NO941581L - Enzymbehandling av glukaner - Google Patents

Enzymbehandling av glukaner

Info

Publication number
NO941581L
NO941581L NO941581A NO941581A NO941581L NO 941581 L NO941581 L NO 941581L NO 941581 A NO941581 A NO 941581A NO 941581 A NO941581 A NO 941581A NO 941581 L NO941581 L NO 941581L
Authority
NO
Norway
Prior art keywords
glucan
yeast
glucans
enzyme treatment
yeast cell
Prior art date
Application number
NO941581A
Other languages
English (en)
Other versions
NO300692B1 (no
NO941581D0 (no
Inventor
Rolf Engstad
Finn Kortner
Boerre Robertsen
Gunnar Roerstad
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19897060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO941581(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Priority to NO941581A priority Critical patent/NO300692B1/no
Publication of NO941581D0 publication Critical patent/NO941581D0/no
Priority to DK95914485T priority patent/DK0759089T3/da
Priority to AU21464/95A priority patent/AU703251B2/en
Priority to AT95914485T priority patent/ATE222958T1/de
Priority to JP52809395A priority patent/JP3992730B2/ja
Priority to PCT/IB1995/000265 priority patent/WO1995030022A1/en
Priority to ES95914485T priority patent/ES2182898T3/es
Priority to EP95914485A priority patent/EP0759089B1/en
Priority to CA2189010A priority patent/CA2189010C/en
Priority to DE69527955T priority patent/DE69527955T2/de
Publication of NO941581L publication Critical patent/NO941581L/no
Priority to FI964339A priority patent/FI114807B/fi
Publication of NO300692B1 publication Critical patent/NO300692B1/no
Priority to US11/093,427 priority patent/US7883875B2/en
Priority to JP2007130872A priority patent/JP2007228974A/ja
Priority to US11/951,811 priority patent/US8142785B2/en
Priority to JP2008290653A priority patent/JP2009051863A/ja
Priority to US12/978,923 priority patent/US8252295B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO941581A 1994-04-29 1994-04-29 Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan NO300692B1 (no)

Priority Applications (16)

Application Number Priority Date Filing Date Title
NO941581A NO300692B1 (no) 1994-04-29 1994-04-29 Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
CA2189010A CA2189010C (en) 1994-04-29 1995-04-18 Enzyme treatment of glucans
AU21464/95A AU703251B2 (en) 1994-04-29 1995-04-18 Enzyme treatment of glucans
EP95914485A EP0759089B1 (en) 1994-04-29 1995-04-18 Enzyme treatment of glucans
DE69527955T DE69527955T2 (de) 1994-04-29 1995-04-18 Behandlung von glucanen mit enzymen
AT95914485T ATE222958T1 (de) 1994-04-29 1995-04-18 Behandlung von glucanen mit enzymen
JP52809395A JP3992730B2 (ja) 1994-04-29 1995-04-18 グルカンの酵素処理
PCT/IB1995/000265 WO1995030022A1 (en) 1994-04-29 1995-04-18 Enzyme treatment of glucans
ES95914485T ES2182898T3 (es) 1994-04-29 1995-04-18 Tratamiento enzimatico de glucanos.
DK95914485T DK0759089T3 (da) 1994-04-29 1995-04-18 Behandling af glucaner med enzymer
FI964339A FI114807B (fi) 1994-04-29 1996-10-28 Glukaanien entsyymikäsittely
US11/093,427 US7883875B2 (en) 1994-04-29 2005-03-30 Method or use of a solubilized glucan product to increase immunostimulation in animals
JP2007130872A JP2007228974A (ja) 1994-04-29 2007-05-16 グルカンの酵素処理
US11/951,811 US8142785B2 (en) 1994-04-29 2007-12-06 Method or use of a solubilized glucan product to increase immunostimulation in animals
JP2008290653A JP2009051863A (ja) 1994-04-29 2008-11-13 免疫刺激組成物を製造するためのグルカンの使用及び薬剤としてのグルカンの使用
US12/978,923 US8252295B2 (en) 1994-04-29 2010-12-27 Enzyme treatment of glucans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO941581A NO300692B1 (no) 1994-04-29 1994-04-29 Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan

Publications (3)

Publication Number Publication Date
NO941581D0 NO941581D0 (no) 1994-04-29
NO941581L true NO941581L (no) 1995-10-30
NO300692B1 NO300692B1 (no) 1997-07-07

Family

ID=19897060

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941581A NO300692B1 (no) 1994-04-29 1994-04-29 Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan

Country Status (12)

Country Link
US (3) US7883875B2 (no)
EP (1) EP0759089B1 (no)
JP (3) JP3992730B2 (no)
AT (1) ATE222958T1 (no)
AU (1) AU703251B2 (no)
CA (1) CA2189010C (no)
DE (1) DE69527955T2 (no)
DK (1) DK0759089T3 (no)
ES (1) ES2182898T3 (no)
FI (1) FI114807B (no)
NO (1) NO300692B1 (no)
WO (1) WO1995030022A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
US8912165B2 (en) 1999-03-12 2014-12-16 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
US6875754B1 (en) 1999-03-12 2005-04-05 Biotec Asa Use of water-soluble β-(1,3) glucans as agents for producing therapeutic skin treatment agents
DE19911055A1 (de) * 1999-03-12 2000-09-21 Cognis Deutschland Gmbh Verwendung von oberflächenaktiven Gemischen
DE19911052A1 (de) 1999-03-12 2000-09-21 Cognis Deutschland Gmbh Sonnenschutzmittel
DE19911058B4 (de) * 1999-03-12 2004-09-30 Biotec Asa Verwendung von nanoskaligen wasserlöslichen β-(1,3)-Glucanen
US8501710B2 (en) * 1999-03-12 2013-08-06 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
DE19911057C2 (de) * 1999-03-12 2001-01-25 Cognis Deutschland Gmbh Haarkosmetische Zubereitungen
DE19911056B9 (de) * 1999-03-12 2005-09-08 Biotec Asa Kosmetische Zubereitungen und deren Verwendung
DE19911053B4 (de) 1999-03-12 2004-10-28 Biotec Asa Kosmetische und/oder pharmazeutische Zubereitungen
DE19917743C2 (de) * 1999-04-20 2003-08-14 Biotec Asa Desodorierende Zubereitungen
DE19917744A1 (de) * 1999-04-20 2000-10-26 Cognis Deutschland Gmbh Dekorative kosmetische Zubereitungen
DE19920557B4 (de) * 1999-05-05 2004-09-09 Biotec Asa Verfahren zur Herstellung von Kollagenfreien kosmetischen Zubereitungen
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
BE1014638A6 (fr) 2002-02-12 2004-02-03 Univ Liege Methode de preparation de derives de la paroi cellulaire a partir de biomasse.
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US20050180964A1 (en) 2003-03-17 2005-08-18 Puntenney Steven B. Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species
JP2004210895A (ja) * 2002-12-27 2004-07-29 Immudyne Japan:Kk 免疫機能を有する可能性β−グルカンの製造方法及び用途
DE602004020117D1 (de) 2004-02-13 2009-04-30 Alpron Co Ltd Verfahren zur herstellung von aus hefe stammendem glucan
US20050220846A1 (en) 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
AU2004218698B2 (en) * 2004-10-08 2011-06-09 Biotec BetaGlucans AS Method
JP4570949B2 (ja) * 2004-12-13 2010-10-27 株式会社アルプロン 酵母由来グルカンの製造方法
BRPI0520481B1 (pt) * 2005-08-10 2020-11-10 Steven Bruce Puntenney composição de b-1, 3 (4) - endoglucanohidrolase, b-1, 3 (4) glucanas, terra diatomácea, argila mineral e glucomananas e método de uso para aumentar a função imunológica
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8142798B2 (en) 2006-04-26 2012-03-27 OmniGen Research, L.L.C. Augmentation of titer for vaccination in animals
US8580253B2 (en) * 2006-11-06 2013-11-12 Whitehead Institute Immunomodulating compositions and methods of use
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2008102151A1 (en) * 2007-02-21 2008-08-28 Biotec Pharmacon Asa Medical uses of glucans
CN101711112B (zh) * 2007-05-08 2015-11-25 生物高聚物工程公司Dba生物治疗公司 粒状可溶的葡聚糖制备
FI20070471A0 (fi) * 2007-06-13 2007-06-13 Glykos Finland Oy Ravinnelisäkompositiota
EP2211900A1 (en) * 2007-11-19 2010-08-04 Calanus AS Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites
US9439954B2 (en) 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
BRPI0900639C1 (pt) * 2009-02-13 2011-12-20 Hebron Farmaceutica Pesquisa Desenvolvimento E Inovacao Tecnologica Ltda composição farmacêutica e uso desta para tratamento e/ou prevenção de doenças do trato respiratório
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
WO2012014978A1 (ja) * 2010-07-29 2012-02-02 国立大学法人北海道大学 免疫アジュバント
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
GB201020193D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
GB201020191D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan gels
GB201020190D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucans
WO2012120290A2 (en) 2011-03-04 2012-09-13 Sana Pharma As Cosmetic formulations
FR2981075A1 (fr) 2011-10-11 2013-04-12 Kitozyme Procede de preparation de glucans a partir d'aspergillus niger
MD4329C1 (ro) * 2013-10-30 2015-09-30 Институт Микробиологии И Биотехнологии Академии Наук Молдовы Procedeu de cultivare a tulpinii de levuri Saccharomyces cerevisiae CNMN-Y-20
WO2015123456A1 (en) 2014-02-12 2015-08-20 OmniGen Research, L.L.C. Composition and method for promoting reduction of heat stress in animals
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
WO2017044832A1 (en) 2015-09-09 2017-03-16 Omnigen Research, Llc A composition and/or combination for aquaculture

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764463A (en) 1953-05-26 1956-09-25 Underwood Corp Magnetic recording system
US3954979A (en) * 1972-11-24 1976-05-04 Ceres Products Company, Inc. Process for preparing stabilized yeast and compositions and tableting composition and method
JPS5432076B2 (no) 1973-09-14 1979-10-11
JPS54138115A (en) * 1978-04-17 1979-10-26 Kirin Brewery Antiicancer agent
GB2076418A (en) 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
JPS6019619B2 (ja) 1980-09-19 1985-05-17 株式会社日立製作所 Ｘ線管用回転陽極
SE456911B (sv) 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
JPS60196195A (ja) 1984-03-21 1985-10-04 Dainippon Seito Kk イ−ストグルカンの製造法
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
CA1330303C (en) 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
JPH05502018A (ja) * 1989-09-08 1993-04-15 アルファ　ベータ　テクノロジー，インコーポレイティッド 免疫系活性化方法
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US6020324A (en) * 1989-10-20 2000-02-01 The Collaborative Group, Ltd. Glucan dietary additives
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan

Also Published As

Publication number Publication date
NO300692B1 (no) 1997-07-07
JP2009051863A (ja) 2009-03-12
JP3992730B2 (ja) 2007-10-17
EP0759089A1 (en) 1997-02-26
CA2189010C (en) 2010-07-13
US8142785B2 (en) 2012-03-27
DK0759089T3 (da) 2003-01-06
FI964339A0 (fi) 1996-10-28
NO941581D0 (no) 1994-04-29
ES2182898T3 (es) 2003-03-16
AU2146495A (en) 1995-11-29
WO1995030022A1 (en) 1995-11-09
FI964339A (fi) 1996-10-28
AU703251B2 (en) 1999-03-25
US8252295B2 (en) 2012-08-28
FI114807B (fi) 2004-12-31
DE69527955D1 (de) 2002-10-02
US20080124349A1 (en) 2008-05-29
JPH09512708A (ja) 1997-12-22
US7883875B2 (en) 2011-02-08
DE69527955T2 (de) 2003-04-10
US20050255565A1 (en) 2005-11-17
JP2007228974A (ja) 2007-09-13
ATE222958T1 (de) 2002-09-15
EP0759089B1 (en) 2002-08-28
CA2189010A1 (en) 1995-11-09
US20110104208A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
NO941581L (no) Enzymbehandling av glukaner
ATE71528T1 (de) Loesliches phosphoryliertes glukan.
AU8596791A (en) Yeast
ES8104407A1 (es) Un metodo de produccion de etanol
Kim et al. Immunomodulating activity of a polysaccharide isolated from Mori Cortex Radicis
DE69431162D1 (en) Fenbendazolformulierungen
Kozhemyakina et al. Conditions of cultivation, composition, and biological activity of mycelium of Flammulina velutipes (Fr.) P. Karst
GB1474313A (en) Process for preparing a protein concentrate from a microbial cell mass and the protein concentrate thus obtained
JPS61139395A (ja) エタノールの製造法
AU7573300A (en) Liberating intracellular matter from biological material
JPS6442412A (en) Skin-beautifying cosmetic
ES8506083A1 (es) Procedimiento para preparar l-aminoacido-oxidasas
WO2001026801A8 (en) Composition of matter tailoring: system i
EP0763852A3 (de) Gehäuse für ein Leistungs-Halbleitermodul
KR880011048A (ko) 분뇨 발효제
EP1237093A3 (en) Methods and apparatus for associating character codes with optimized character codes
管兆勇 et al. Atmospheric wave and its physical essence as revealed by changed correlation coefficients and correlation field
KR920012448A (ko) 홍국균의 배양방법 및 홍국색소 추출방법
Fachet et al. Lipid peroxidation and SOD activity in liver and membrane-microviscosity of macrophages in lentinan-treated tumor-bearing mice
Rusinov Linear selection of highly productive strains of Penicillium chrysogenum
Janusz et al. Isolation of a unit ligand for β-glucan receptors of human monocytes
MY124118A (en) Organometallic-metabolizing yeast
Ábel et al. Effect of lentinan treatment on endocytic functions of peritoneal macrophages in tumor-bearing mice
PE20020313A1 (es) Nueva mezcla de oligosacaridos no sulfatados a base de fucosa, composicion cosmetica o farmaceutica que la comprende
UA11935A1 (uk) Гібридhий штам дріжджів sассhаrомyсеs сеrеvіsіае, який використовується для одержання хлібопекарських дріжджів

Legal Events

Date Code Title Description
MK1K Patent expired